You are here: Industry Insights > Novartis

News List

In Second Gene Therapy Buy of the Year, Novartis Acquires AveXis for $8.7B biospace
April 10, 2018
Swiss-based Novartis has struck a deal to acquire Bannockburn, Illinois-based AveXis for $8.7 billion.
GSK to buyout consumer healthcare business from Novartis for $13bn pharmaceutical-technology
April 09, 2018
GlaxoSmithKline has agreed to buy Novartis’ 36.5% stake in the companies’ consumer healthcare joint venture for $13bn.
Lawsuits Allege Safety Concern Over Novartis CML Drug Tasigna biospace
March 30, 2018
A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.
With Cash in Hand, Novartis Could Seek Deal to Bolster Drug Pipeline biospace
March 29, 2018
The sale of the consumer health product business is a signal that the company intends to focus its resources on drug development. But what could that look like
GSK to pay $13bn for Novartis stake in OTC joint venture pharmaphorum
March 28, 2018
GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture, and may sell its Horlicks business to fund the £9.2 billion ($13bn) acquisition.
Novartis Kicks Alcon Spinoff Decision Down the Road to Mid-2019 biospace
March 28, 2018
Novartis chief executive officer Vasant Narasimhan confirms that any decision about spinning off its Alcon eye care business won’t be made until the first half of 2019.
After Spurning Pfizer GlaxoSmithKline Cuts $13B Deal with Novartis biospace
March 28, 2018
GlaxoSmithKline walked away from a potential deal to acquire Pfizer’s consumer health unit four days ago and instead opted to invest in its own consumer unit.
Novartis, Harvard team up for cancer immunotherapies biospectrumasia
March 26, 2018
Novartis will have worldwide rights, in target-limited applications, to bring the biomaterial-based cancer immunotherapies into clinical development and translate this approach to treat patients.
Novartis Published Multiple Sclerosis Trial Data With Plans to File for FDA Approval biospace
March 26, 2018
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
Novartis drug Tasigna approved by FDA to treat children with rare form of leukemia firstwordpharma
March 23, 2018
Novartis announced today that the FDA expanded the indication for Tasigna® to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page